Cleveland-based Athersys, Inc., has entered into an agreement with Pfizer Inc. to develop and commercialize a new treatment for Inflammatory Bowel Disease, the company says in a news release.
Under the terms of the agreement, Athersys will receive an up-front cash payment of $6 million from Pfizer, as well as research funding and support during the initial phase of the collaboration.
Read the full story
here.